Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer

Journal of Pathology

Volumn 228, Issue 2, 2012, Pages 241-250

  Zhang, Jingdong ^a,b   Wang, Peng ^a   Dykstra, Mark ^a   Gelebart, Pascale ^a   Williams, David ^a   Ingham, Robert ^a   Adewuyi, Esther Ekpe ^a   Lai, Raymond ^a   McMullen, Todd ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

metastases; papillary thyroid cancer; platelet derived growth factor receptor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; SUNITINIB;

ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS;

EID: 84866258490     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4069     Document Type: Article

References (42)

1. Dean DS, Gharib H,. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008; 22: 901-911.
2. Gharib H, Goellner Jr,. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med 1993; 118: 282-289.
3. Yip L, Kebebew E, Milas M, et al., Summary statement: utility of molecular marker testing in thyroid cancer. Surgery 2010; 148: 1313-1315.
4. Shaha AR, Shah J, Loree TR,. Patterns of failure in differentiated carcinoma of the thyroid based on risk groups. Head Neck 1998; 20: 26-30.
5. Cooper DS, Doherty GM, Haugen BR, et al., Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009; 19: 1167-1214.
6. Machens A, Hinze R, Thomusch O, et al., Pattern of nodal metastasis for primary and reoperative thyroid cancer. World J Surg 2002; 26: 22-28.
7. Ito Y, Miyauchi A,. Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma. World J Surg 2008; 32: 729-739.
8. Rotstein L,. The role of lymphadenectomy in the management of papillary carcinoma of the thyroid. J Surg Oncol 2009; 99: 186-188.
9. Lundgren CI, Hall P, Dickman PW, et al., Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006; 106: 524-531.
10. Shibru D, Chung KW, Kebebew E,. Recent developments in the clinical application of thyroid cancer biomarkers. Curr Opin Oncol 2008; 20: 13-18.
11. Taccaliti A, Boscaro M,. Genetic mutations in thyroid carcinoma. Minerva Endocrinol 2009; 34: 11-28.
12. DeLellis RA,. Pathology and genetics of thyroid carcinoma. J Surg Oncol 2006; 94: 662-669.
13. Marchetti I, Lessi F, Mazzanti CM, et al., A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid 2009; 19: 837-842.
14. Griffith OL, Melck A, Jones SJ, et al., Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006; 124: 5043-5051.
15. Nikiforov YE,. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008; 21: S37-S43.
16. Nikiforov YE, Ohori NP, Hodak SP, et al., Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011; 96: 3390-3397.
17. Lee SH, Lee JK, Jin SM, et al., Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma. Otolaryngol Head Neck Surg 2010; 142: 332-337.
18. Liang H, Zhong Y, Luo Z, et al., Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. Int J Biol Markers 2010; 25: 38-45.
19. Zhu X, Sun T, Lu H, et al., Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol 2010; 63: 786-789.
20. Homsi J, Daud AI,. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007; 14: 285-294.
21. Provencio M, García-Campelo R, Isla D, et al., Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clin Transl Oncol 2009; 11: 428-436.
22. Liu J, Liao S, Huang Y, et al., PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011; 17: 3638-3648.
23. Lei H, Velez G, Kazlauskas A,. Pathological signaling via platelet-derived growth factor receptor {alpha} involves chronic activation of Akt and suppression of p53. Mol Cell Biol 2011; 31: 1788-1799.
24. Cornellà H, Alsinet C, Villanueva A,. Molecular pathogenesis of hepatocellular carcinoma. Alcohol Clin Exp Res 2011; 35: 821-825.
25. Yano Y, Uematsu N, Yashiro T,. Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 2004; 10: 2035-2043.
26. Bruland O, Fluge O, Akslen LA, et al., Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer 2009; 9: 425-432.
27. Wang Y, Ji M, Wang W, et al., Association of the T1799A BRAF mutation with tumour extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer. Endocr Relat Cancer 2008; 15: 183-190.
28. Sherman SI,. Targeted therapies for thyroid tumors. Mod Pathol 2011; 24: S44-S52.
29. Gild ML, Bullock M, Robinson BG, et al., Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nature Rev Endocrinol 2011; 7: 617-624.
30. Romagnoli S, Moretti S, Voce P, et al., Targeted molecular therapies in thyroid carcinoma. Arq Bras Endocrinol Metabol 2009; 53: 1061-1073.
31. Gupta-Abramson V, Troxel AB, Nellore A, et al., Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26: 4714-4719.
32. Kloos RT, Ringel MD, Knopp MV, et al., Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27: 1675-1684.
33. Carr LL, Mankoff DA, Goulart BH, et al., Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16: 5260-5268.
34. Brose MS, Nutting CM, Sherman SI, et al., Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. BMC Cancer 2011; 11: 349-356.
35. González-Cámpora R, Delgado MD, Amate AH, et al., Old and new immunohistochemical markers for the diagnosis of gastrointestinal stromal tumors. Anal Quant Cytol Histol 2011; 33: 1-11.
36. Barreca A, Fornari A, Bonello L, et al., KIT and PDGFRA mutations and PDGFRA immunostaining in gastrointestinal stromal tumors. Mol Med Rep 2011; 4: 3-8.
37. Wang P, Wu F, Zhang J, et al., Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential. Carcinogenesis 2011; 32: 146-153.
38. Schweppe R, Klopper J, Korch C, et al., Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008; 93: 4331-4341.
39. Russell MR, Liu Q, Lei H, et al., The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Res 2010; 70: 4195-4203.
40. Eckert MA, Lwin TM, Chang AT, et al., Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011; 19: 372-386.
41. Liu Z, Hou P, Ji M, et al., Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab 2008; 93: 3106-3116.
42. Farooqi AA, Waseem S, Riaz AM, et al., PDGF: the nuts and bolts of signalling toolbox. Tumour Biol 2011; 32:1057- 1070.